keyword
MENU ▼
Read by QxMD icon Read
search

melanoma Stage 3

keyword
https://www.readbyqxmd.com/read/29912415/primary-melanoma-histologic-subtype-impact-on-survival-and-response-to-therapy
#1
Michael Lattanzi, Yesung Lee, Danny Simpson, Una Moran, Farbod Darvishian, Randie H Kim, Eva Hernando, David Polsky, Doug Hanniford, Richard Shapiro, Russell Berman, Anna C Pavlick, Melissa A Wilson, Tomas Kirchhoff, Jeffrey S Weber, Judy Zhong, Iman Osman
Background: Two primary histologic subtypes, superficial spreading melanoma (SSM) and nodular melanoma (NM), comprise the majority of all cutaneous melanomas. NM is associated with worse outcomes, which have been attributed to increased thickness at presentation, and it is widely expected that NM and SSM would exhibit similar behavior once metastasized. Herein, we tested the hypothesis that primary histologic subtype is an independent predictor of survival and may impact response to treatment in the metastatic setting...
June 15, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29908991/mage-a3-immunotherapeutic-as-adjuvant-therapy-for-patients-with-resected-mage-a3-positive-stage-iii-melanoma-derma-a-double-blind-randomised-placebo-controlled-phase-3-trial
#2
Brigitte Dreno, John F Thompson, Bernard Mark Smithers, Mario Santinami, Thomas Jouary, Ralf Gutzmer, Evgeny Levchenko, Piotr Rutkowski, Jean-Jacques Grob, Sergii Korovin, Kamil Drucis, Florent Grange, Laurent Machet, Peter Hersey, Ivana Krajsova, Alessandro Testori, Robert Conry, Bernard Guillot, Wim H J Kruit, Lev Demidov, John A Thompson, Igor Bondarenko, Jaroslaw Jaroszek, Susana Puig, Gabriela Cinat, Axel Hauschild, Jelle J Goeman, Hans C van Houwelingen, Fernando Ulloa-Montoya, Andrea Callegaro, Benjamin Dizier, Bart Spiessens, Muriel Debois, Vincent G Brichard, Jamila Louahed, Patrick Therasse, Channa Debruyne, John M Kirkwood
BACKGROUND: Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic in patients with stage IIIB or IIIC melanoma in the adjuvant setting. METHODS: DERMA was a phase 3, double-blind, randomised, placebo-controlled trial done in 31 countries and 263 centres. Eligible patients were 18 years or older and had histologically proven, completely resected, stage IIIB or IIIC, MAGE-A3-positive cutaneous melanoma with macroscopic lymph node involvement and an Eastern Cooperative Oncology Group performance score of 0 or 1...
June 13, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29894722/clinicopathological-immunohistochemical-and-molecular-correlation-of-neural-crest-transcription-factor-sox10-expression-in-triple-negative-breast-carcinoma
#3
Aparna Harbhajanka, Satyapal Chahar, Kristy Miskimen, Paula Silverman, Lyndsay Harris, Nicole Williams, Vinay Varadan, Hannah Gilmore
The transcription factor SOX10 mediates the differentiation of neural crest-derived cells, and SOX10 by immunohistochemistry(IHC) is used primarily for the diagnosis of melanoma. SOX10 expression has been previously documented in benign breast myoepithelial cells. However there is limited literature on its expression in triple negative breast carcinoma(TNBC). The aim was to study the clinical, pathologic and molecular profiles of SOX10+ tumors in TNBC. Tissue microarrays of TNBC were evaluated for SOX10 expression in 48cases...
June 9, 2018: Human Pathology
https://www.readbyqxmd.com/read/29894582/in-situ-nail-unit-melanoma-epidemiological-and-clinic-pathologic-features-with-conservative-treatment-and-long-term-follow-up
#4
Sophie Goettmann, Isabelle Moulonguet, Inès Zaraa
BACKGROUND: Nail unit melanoma (NUM) is a rare melanoma variant, usually associated with a poor prognosis because of a delayed diagnosis. Few data are available concerning the management and long-term outcome of in situ NUM. OBJECTIVE: To use a large cohort to provide comprehensive patient data and long-term follow-up information. This will serve to investigate distinctive epidemiological, clinical, and histological features of in situ NUM. to report treatment modalities, assess conservative surgery and evaluate its long-term safety...
June 12, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29891725/pembrolizumab-exposure-response-assessments-challenged-by-association-of-cancer-cachexia-and-catabolic-clearance
#5
David Turner, Anna G Kondic, Keaven M Anderson, Andrew Robinson, Edward B Garon, Jonathan W Riess, Lokesh Jain, Kapil Mayawala, Jiannan Kang, Scot W Ebbinghaus, Vikram Sinha, Dinesh P de Alwis, Julie A Stone
PURPOSE: To investigate the relationship of pembrolizumab pharmacokinetics (PK) and overall survival (OS) in patients with advanced melanoma and non-small cell carcinoma (NSCLC). EXPERIMENTAL DESIGN: PK dependencies in OS were evaluated across three pembrolizumab studies of either 200mg or 2-10 mg/kg Q3W. Kaplan-Meier (K-M) plots of OS, stratified by dose, exposure, and baseline clearance were assessed per indication and study. A Cox Proportional Hazards model was implemented to explore imbalances of typical prognostic factors in high/low NSCLC CL</SPAN>0 <SPAN style="font-family: Arial, sans-serif;"> subgroups...
June 11, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29847461/metastatic-acral-lentiginous-melanoma-in-a-tertiary-referral-center-in-switzerland-a-systematic-analysis
#6
Esther M Häfliger, Egle Ramelyte, Joanna Mangana, Michael Kunz, Dmitry V Kazakov, Reinhard Dummer, Phil F Cheng
Acral lentiginous melanoma (ALM) is a unique histopathological subtype of melanoma with a poorer prognosis than other cutaneous melanomas. This study aims to evaluate the clinicopathological characteristics, metastatic pattern, prognostic factors, response to systemic therapy, and overall survival (OS) of ALM in a White population. This is a retrospective study of patients who were diagnosed and/or treated for ALM at the Department of Dermatology of the University Hospital Zurich, Switzerland, from January 2005 to December 2015...
May 29, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29805617/mage3-and-survivin-activated-dendritic-cell-immunotherapy-for-the-treatment-of-non-small-cell-lung-cancer
#7
Dong Li, Song He
Dendritic cell (DC) immunotherapy is an optimal cancer treatment, resulting in its emergence as a therapeutic choice; however, there are limited studies investigating dual antigen-pulsed DC immunotherapy in non-small cell lung cancer (NSCLC). In order to determine the effect of a recombinant melanoma-associated antigen (rMAGE-3) and recombinant Survivin (rSurvivin) peptide-pulsed DC immunotherapy in patients with NSCLC, the present clinical study was performed. DC immunotherapy was generated from the monocytes of patients with NSCLC and primed with rMAGE-3 and rSurvivin peptides...
June 2018: Oncology Letters
https://www.readbyqxmd.com/read/29800566/genome-wide-rnai-screen-identify-melanoma-associated-antigen-mageb3-involved-in-x-chromosome-inactivation
#8
Wei Li, Ru Hong, Lan-Tian Lai, Qiman Dong, Peiling Ni, Rosi Chelliah, Mehnaz Huq, Siti Nadirah Binte Ismail, Udita Chandola, Zhiwei Ang, Bingqing Lin, Xin Chen, Lingyi Chen, Li-Feng Zhang
Xist (inactivated X chromosome specific transcript) is a prototype long non-coding RNA (lncRNA) in charge of epigenetic silencing of one X chromosome in each female cell in mammals. In a genetic screen, we identify Mageb3, and its homologs Mageb1 and Mageb2 as genes functionally required for Xist-mediated gene silencing. Mageb1-3 are previously uncharacterized genes belonging to the MAGE (melanoma-associated antigen) gene family. Mageb1-3 are expressed in undifferentiated ES cells and early stages of in vitro differentiation, a critical time window of X chromosome inactivation...
May 22, 2018: Journal of Molecular Biology
https://www.readbyqxmd.com/read/29799979/assessment-of-frontalis-myocutaneous-transposition-flap-for-forehead-reconstruction-after-mohs-surgery
#9
Alejandra Tomás-Velázquez, Pedro Redondo
Importance: Forehead reconstruction after Mohs surgery has become a challenge for dermatology surgeons, and achieving an excellent cosmetic and functional result is imperative in this location. Objective: To highlight the utility of a frontalis myocutaneous transposition flap (FMTF) for forehead reconstruction after Mohs surgery. Design, Setting, and Participants: Surgical technique case series including 12 patients with large forehead defects recruited between January 2010 and June 2017 at the Dermatology Department of the University Clinic of Navarra, Spain...
May 16, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/29796159/analysis-of-kit-gene-mutations-in-patients-with-melanoma-of-the-head-and-neck-mucosa-a-retrospective-clinical-report
#10
Ullyanov Bezerra Toscano de Mendonça, Claudio Roberto Cernea, Leandro Luongo Matos, Roberto Rego Monteiro de Araujo Lima
Unlike their cutaneous counterparts, head and neck mucosal malignant melanomas (HNMM) are more aggressive, and their prognostic markers have not been fully elucidated. This study, comprising 28 patients with HNMM, aimed to establish the relationship between different mutations and outcome, define the incidence of KIT mutations in HNMM, and identify the correlation among therapeutic options, histopathological findings, demographic data, and clinical response. Clinical analysis included patient characteristics, staging, primary and palliative treatments, and disease-free survival and overall survival (OS)...
May 1, 2018: Oncotarget
https://www.readbyqxmd.com/read/29785325/screening-for-malignant-melanoma-a-critical-assessment-in-historical-perspective
#11
Wolfgang Weyers
Screening for melanoma has been advocated for many years because early detection and excision have been regarded as the most important measure to lower mortality from that neoplasm. In the past decade, concern has been raised by epidemiologists that screening might result in excision chiefly of "inconsequential cancer," i.e., melanomas that would never have progressed into life-threatening tumors, a phenomenon referred to by the misleading term "overdiagnosis." Without any firm evidence, that speculation has been embraced worldwide, and incipient melanomas have been trivialized...
April 2018: Dermatology Practical & Conceptual
https://www.readbyqxmd.com/read/29776954/role-of-elevated-phip-copy-number-as-a-prognostic-and-progression-marker-for-cutaneous-melanoma
#12
Vladimir Bezrookove, Mehdi Nosrati, James R Miller, David de Semir, Altaf A Dar, Elham Vosoughi, Edith Vaquero, Antje Sucker, Alexander J Lazar, Jeffrey E Gershenwald, Michael A Davies, Dirk Schadendorf, Mohammed Kashani-Sabet
PURPOSE: Previous studies have indicated an important role for pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. Here we aimed to confirm the role of PHIP copy number in successive stages of melanoma progression. EXPERIMENTAL DESIGN: PHIP copy number was examined using fluorescence in situ hybridization (FISH) in three independent cohorts by recording the percentage of cells harboring &gt; 3 copies of PHIP...
May 18, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29766492/nivolumab-versus-ipilimumab-in-the-treatment-of-advanced-melanoma-a-critical-appraisal
#13
M T Wan, M E Ming
AIM: To show whether either nivolumab in combination with ipilimumab or nivolumab monotherapy vs. ipilimumab monotherapy extends overall survival (OS) or progression-free survival (PFS) in adults with previously untreated, advanced melanoma. SETTING AND DESIGN: The trial was conducted at 137 sites in 21 countries. Randomization (n = 945; 1 : 1 : 1 ratio) was stratified according to metastasis stage, BRAF mutation status and programmed death ligand 1 status. STUDY EXPOSURE: Adults were randomized to one of the following: nivolumab plus ipilimumab every 3 weeks for four doses, followed by nivolumab every 2 weeks; nivolumab every 2 weeks plus placebo; or ipilimumab every 3 weeks for four doses plus placebo...
May 15, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29765544/comparison-of-infectivity-and-spread-between-hsv-1-and-hsv-2-based-oncolytic-viruses-on-tumor-cells-with-different-receptor-expression-profiles
#14
Xinping Fu, Lihua Tao, Pin-Yi Wang, Timothy P Cripe, Xiaoliu Zhang
Herpes simplex virus (HSV) is one of the many viruses that have been modified or adapted for oncolytic purposes. There are two serotypes of HSV, HSV-1 and HSV-2. The majority of oncolytic HSVs, including T-VEC which has recently been approved by the US Food and Drug Administration (FDA) for clinical use in treating late stage melanoma patients, are derived from HSV-1. Recently, we and others have developed several HSV-2 based oncolytic viruses. During our in vitro characterization of oncolytic viruses developed from both serotypes (Baco-1 from HSV-1 and FusOn-H2 from HSV-2), we noticed there is a subpopulation of cancer cells in which both viruses could infect but only FusOn-H2 could spread from cell to cell on monolayers...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29764498/talimogene-laherparepvec-combined-with-anti-pd-1-based-immunotherapy-for-unresectable-stage-iii-iv-melanoma-a-case-series
#15
Lillian Sun, Pauline Funchain, Jung Min Song, Patricia Rayman, Charles Tannenbaum, Jennifer Ko, Michael Mcnamara, C Marcela Diaz-Montero, Brian Gastman
BACKGROUND: Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma. The mechanisms of action for T-VEC and checkpoint inhibitor are highly complementary. Recent studies have shown that combining checkpoint inhibitor therapy with T-VEC injection can lead to improved response rates for stage IIIB-IV melanoma patients. METHODS: We reviewed 10 consecutive cases of stage IIIC to stage IVM1b melanoma patients that received T-VEC plus checkpoint inhibitor(s) therapy (pembrolizumab, ipilimumab/nivolumab, or nivolumab) treated between June 2016 and August 2017 at the Cleveland Clinic with a median follow-up of 7 months (range: 4 to 13 months)...
May 16, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29764330/factors-influencing-the-provision-of-fertility-counseling-and-impact-on-quality-of-life-in-adolescents-and-young-adults-with-cancer
#16
Gemma Skaczkowski, Victoria White, Kate Thompson, Helen Bibby, Michael Coory, Lisa M Orme, Rachel Conyers, Marianne B Phillips, Michael Osborn, Rosemary Harrup, Antoinette Anazodo
PURPOSE: This study investigated the impact of fertility-related discussions on Adolescent and Young Adult (AYA) cancer patients' quality of life (QoL) and the factors influencing provision of these discussions. METHODS: Recruitment was conducted through population-based state cancer registries. Eligible AYAs were 15-24 years at diagnosis, 3-24 months postdiagnosis, with any cancer (except early stage melanoma). As part of a larger survey, AYAs were asked about their experiences of fertility-related discussions and QoL (FACT-G)...
May 15, 2018: Journal of Psychosocial Oncology
https://www.readbyqxmd.com/read/29747688/immune-checkpoint-inhibitor-induced-diarrhea-and-colitis-in-patients-with-advanced-malignancies-retrospective-review-at-md-anderson
#17
Yinghong Wang, Hamzah Abu-Sbeih, Emily Mao, Noman Ali, Faisal Shaukat Ali, Wei Qiao, Phillip Lum, Gottumukkala Raju, Gladis Shuttlesworth, John Stroehlein, Adi Diab
BACKGROUND: Immune checkpoint inhibitors (ICPIs) are gaining increasing popularity as an efficacious treatment for advanced malignancies. ICPI treatment can be complicated by diarrhea and colitis. Systemic steroids are the first line treatment. Infliximab is reserved for severe refractory cases. We aimed to assess the impact of ICPI-induced diarrhea and colitis and their immunosuppressive treatment on patients' outcomes. METHODS: This retrospective analysis was conducted in 327 cancer patients who received ICPIs between 2011 and 2017...
May 11, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29747595/the-search-for-a-melanoma-tailored-chemotherapy-in-the-new-era-of-personalized-therapy-a-phase-ii-study-of-chemo-modulating-temozolomide-followed-by-fotemustine-and-a-cooperative-study-of-goim-gruppo-oncologico-italia-meridionale
#18
Michele Guida, Stefania Tommasi, Sabino Strippoli, Maria Iole Natalicchio, Simona De Summa, Rosamaria Pinto, Antonio Cramarossa, Anna Albano, Salvatore Pisconti, Michele Aieta, Ruggiero Ridolfi, Amalia Azzariti, Gabriella Guida, Vito Lorusso, Giusepe Colucci
BACKGROUND: It is frequently asked whether chemotherapy can still play a role in metastatic melanoma considering the effectiveness of the available drugs today, including antiCTLA4/antiPD1 immunotherapy and antiBRAF/antiMEK inhibitors. However, only approximately half of patients respond to these drugs, and the majority progress after 6-11 months. Therefore, a need for other therapeutic options is still very much apparent. We report the first large trial of a sequential full dose of fotemustine (FM) preceded by a low dose of temozolomide (TMZ) as a chemo-modulator in order to inactivate the DNA repair action of O(6)-methylguanine DNA-methyltransferase (MGMT)...
May 10, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29746316/the-clinical-significance-of-kit-mutations-in-melanoma-a-meta-analysis
#19
Hui Z Gong, He Y Zheng, Jun Li
This study aimed to evaluate the association of KIT mutations with clinicopathologic features of melanomas using a meta-analysis and to identify differences between Asian and White populations using subgroup analyses. We selected 32 studies from the literature including 5224 patients. The pooled data were combined, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Heterogeneity and publication bias were also determined. KIT mutations were reported in 497 (9.5%) of 5224 patients with melanomas, and were associated significantly with age, clinical melanoma subtype, anatomic location, and chronic sun-damage (CSD), but not with sex, histological type, Breslow thickness, ulceration, mitotic rate, or tumor stage...
May 9, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29734677/the-effect-of-bornyl-cis-4-hydroxycinnamate-on-melanoma-cell-apoptosis-is-associated-with-mitochondrial-dysfunction-and-endoplasmic-reticulum-stress
#20
Tzu-Yen Yang, Yu-Jen Wu, Chi-I Chang, Chien-Chih Chiu, Mei-Li Wu
Bornyl cis -4-hydroxycinnamate, an active compound isolated from Piper betle stems, was investigated in terms of its effects on A2058 and A375 melanoma cell proliferation and protein expression in this study. We used flow cytometric analysis to examine the early stages of apoptosis induced by bornyl cis -4-hydroxycinnamate in the two melanoma cell lines and employed comparative proteomic analysis to investigate the effects of this compound on protein expression in A375 cells. Master maps generated by PDQuest software from two-dimensional electrophoresis (2-DE) analysis of A375 cells showed that the expression levels of 35 proteins were significantly altered, with 18 proteins upregulated and 17 downregulated...
May 4, 2018: International Journal of Molecular Sciences
keyword
keyword
62301
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"